Aakaar Medical Technologies Limited is a premier Indian medical aesthetics company specializing in the manufacturing and distribution of advanced aesthetic products and medical devices. Operating a **B2B** model, the company serves a professional client base of over **5,236** practitioners, including dermatologists, plastic surgeons, and aesthetic specialists. Aakaar is currently executing a strategic pivot from a distribution-centric model to a high-margin, brand-led strategy focused on regenerative medicine and USFDA-approved technologies. --- ### **Strategic Business Architecture & Revenue Streams** The company operates through a dual-segment model designed to balance recurring revenue with high-value capital equipment. * **Manufacturing & Owned Brands:** Aakaar is aggressively shifting toward owned high-margin brands to mitigate **forex volatility** and capture higher operating leverage. It utilizes an **asset-light strategy**, partnering with leading **CRDMOs** for production while retaining control over formulation, marketing, and clinical validation. * **In-Licensing & Distribution:** Approximately **70%** of the topline is currently driven by exclusive in-licensing agreements with global leaders from **Korea, Spain, Italy, and Austria**. * **Product Mix:** Aesthetic products (injectables, peels, and topicals) account for **83%** of the business, providing a stable recurring revenue base. The portfolio currently comprises **154 SKUs**, with a target to reach **164** by 2026. #### **Divisional Performance (FY25)** | Division | Focus Area | Revenue (FY25) | YoY Growth | | :--- | :--- | :--- | :--- | | **Innovea** | Core Skincare & Peels (Largest Base) | **INR 24 Cr.** | **57%** | | **Thervea** | High-Growth Therapeutics | **INR 14 Cr.** | **105%** | | **Rejuvea** | Regenerative & Anti-Aging | **INR 14 Cr.** | **27%** | | **Exovea** | New Launch: Synthetic Exosomes | **INR 6 Cr.** (Proj. Yr 1) | N/A | | **Techvea** | Consumable Devices | N/A | N/A | --- ### **Global Partnerships & Product Innovation** Aakaar maintains long-term exclusive distribution agreements with international pioneers, ensuring a pipeline of **USFDA-approved** and clinically validated products. * **Key Partners:** * **Mesoestetic (Spain):** Partner since **2010**; experts in aesthetic medicine. * **Theraderm (US/Korea):** Partner since **2011**; focused on stem cell and silk proteins. * **Medy-Tox (South Korea):** Partner since **2017**; specialists in botulinum toxin and fillers. * **Croma-Pharma (Austria):** Partner since **2018**; global leader in hyaluronic acid syringes. * **Regenera Activa (Spain):** Partner since **2023**; biotech focused on dermatology. * **Flagship Innovations:** * **EXOVEA (Exosomes):** Launched in late 2025 in partnership with **VM Corporation (Italy)**. This division introduces India’s first **Synthetic Exosome** platform using **SuperExo™** technology (supercritical $CO_2$ extraction) for ultra-pure, shelf-stable vesicles. * **Letybo® (Botulinum Toxin):** Secured import license for this **USFDA-approved** toxin via **Hugel**. Commercial launch is set for **April 2026**, featuring **50 IU vials** to penetrate Tier-2 and Tier-3 markets. * **Saypha® (Dermal Fillers):** A **USFDA-approved** hyaluronic acid filler from **Croma-Pharma**, positioned to compete with top-tier global brands. --- ### **Operational Infrastructure & Market Engagement** The company utilizes a nationwide distribution backbone designed for zero capital intensity and rapid scalability. * **Logistics & Supply Chain:** **80%** of sales flow through **21 hubs** managed by PISPL, ensuring a scale-ready supply chain. The remaining **20%** is handled via direct outreach and a network of **20+ pharmacies/stockists**. * **Sales Force:** Supported by over **100 MR executives** engaging directly with **14,000 doctors** across India. This "doctor-dispensed" model reduces reliance on traditional digital marketing spend. * **Clinical Training:** Aakaar drives adoption through its **MICA (Masterclass in Contouring Aesthetics)** program, having conducted over **950 workshops** and participating in **600+** international and national conferences (e.g., DERMACON). * **Inventory Management:** Current inventory is maintained at a **90 to 120-day** period. Temporary elevations in 2025 were due to regulatory re-licensing and revised packaging requirements following the company's conversion to a Public Limited entity. --- ### **Financial Performance & Capital Structure** Aakaar has demonstrated a robust growth trajectory, significantly outperforming the Indian aesthetic market’s **14% CAGR**. #### **Annual Financial Summary** | Metric | FY 2022-23 | FY 2023-24 | FY 2024-25 | YoY Growth (FY25) | | :--- | :--- | :--- | :--- | :--- | | **Revenue from Operations** | ₹19.46 Cr | ₹46.11 Cr | **₹61.58 Cr** | **+33.55%** | | **EBITDA** | - | ₹5.15 Cr | **₹10.00 Cr** | **+94.00%** | | **EBITDA Margin** | - | 10.80% | **16.15%** | **+535 bps** | | **Profit After Tax (PAT)** | ₹2.02 Cr | ₹2.91 Cr | **₹6.03 Cr** | **+107.00%** | * **IPO & Fund Utilization:** Listed on **NSE Emerge** in **June 2025**, raising **₹27 Cr**. Proceeds are earmarked for **working capital** (**₹20 Cr** across FY26-27) to reduce dependence on short-term borrowing. * **H1 FY 2025-26 Trends:** Revenue stood at **₹25.3 Cr** (down **8.6% YoY**), reflecting a deliberate tightening of **credit terms** to improve cash realization and seasonal transitions. Management targets a **positive PAT** rebound in H2. * **Efficiency Targets:** The company aims to normalize receivable days to **60 days** by **FY28** (a **60%** reduction from current levels) to achieve consistent **positive cash flow**. --- ### **Risk Factors & Contingency Management** As Aakaar scales, it manages several operational and regulatory risks inherent to the medical technology sector. * **Forex & Procurement:** Procurement costs are sensitive to **USD/EUR** fluctuations. The company maintains strategic import buffers to mitigate risks during **license renewals** and **CDSCO/Local FDA** reviews. * **Working Capital & Debt:** Short-term borrowings from **ICICI Bank** at **7.9%** interest are used for operations. The company is actively working to reduce inventory pressure caused by **packaging MOQs**. * **Legal Contingencies:** * **Customs Dispute:** **₹40,00,000** deposit for a bank guarantee; recoverability depends on legal outcomes. * **Consumer Litigation:** A **₹35,00,000** claim regarding equipment service (Case No. 184/2023). The company has deposited the full amount with the **Telangana State Commission** and a stay has been granted pending appeal. * **Regulatory Transition:** The shift from Private to Public status required a comprehensive realignment of compliance and internal processes, which is now largely stabilized.